The utility of microtubule-associated protein 2 (MAP2) immunostaining as a marker of acute focal isch emic injury was investigated. Permanent middle cerebral artery occlusion (MeAO) elicited a rapid reduction in MAP2 immunostaining that was visible 1 h post-MeAO and that increased in intensity and area encompassed over time. The ischemic lesion borders were well defined by loss of MAP2 immunostaining, but alterations in stain-Lesion volume in rodent models of focal cerebral ischemia may reach its maximum level within a rel atively short time period. Thus, pathological pro cesses initiated within the first few hours of an isch emic insult are likely to have a greater impact on outcome than later events. To investigate such acute pathological processes, it is necessary to have an indicator of ischemic injury that can reliably de lineate the lesion at correspondingly early time points. Although conventional histological tech niques such as triphenyltetrazolium chloride and hematoxylin and eosin (H&E) staining have been employed within 4 h of permanent focal ischemia (Tamura et aI., 198 1; Hatfield et aI., 199 1), their use is limited since triphenyltetrazolium chloride im mersion staining may be unreliable for the quantifi-
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ing within the lesion were more heterogeneous. Lesion volume increased significantly from 1 to 4 h post-MeAO (from 63.8 ± 10.8 to 111.3 ± 19.0 mm3, mean ± SD). Thus, MAP2 immunostaining is a sensitive, quantifiable indicator of acute brain injury following focal ischemia. Key Words: Histology-Immunohistochemistry Ischemia-Microtubule-associated protein 2-Neuronal injury.
cation of acute ischemic damage (Hatfield et aI., 199 1) , while H&E staining (at early time points) is difficult to interpret without extensive neuropatho logical expertise. As an alternative approach, isch emia-induced reduction in microtubule-associated protein 2 (MAP2) immunostaining has received con siderable attention as a marker of early damage fol lowing transient global ischemia (Yanagihara et aI., 1990; Tomioka and Yanagihara, 1992; Miyazawa et aI., 1993) , and therefore we decided to assess the utility of this technique as a marker of acute neuro nal injury in the context of permanent focal isch emia.
MAP2 is one of a family of MAPs involved in maintaining the structural integrity of the neuronal cytoskeleton and modulating synaptic plasticity (Johnson and Jope, 1992) . Under normal condi tions, MAP2 is almost exclusively located in neu rons and represents an effective somatodendritic la bel (De Camilli et aI., 1984) . While loss of MAP2 immunostaining has proven to be a highly sensitive marker of ischemic injury following transient global ischemia (Yanagihara et aI., 1990; Miyazawa et aI., 1993) , its use has, until now, been predominantly restricted to a purely qualitative description of neu ronal injury. Thus, the current study is novel in that it not only represents one of the first detailed at tempts to use this technique for permanent focal ischemia, but it also exploits loss of MAP2 immu no staining to quantify lesion volume in the acute time period following onset of ischemia.
METHODS
Adult male (300-350 g) spontaneously hypertensive rats underwent permanent middle cerebral artery occlu sion (MCAO) of 1-, 2-, or 4-h duration (n = 5 per group). Rats were anesthetized with halothane (5% for induction, 1-1.5% for maintenance) in nitrous oxide/oxygen (70:30) and artificially ventilated. Blood pressure, arterial blood gases, and body temperature were monitored at regular intervals. The left MCA was exposed using a subtemporal approach (Tamura et aI., 1981) , occluded by electrocoag ulation midway between the inferior cerebral vein and olfactory tract, then severed to prevent recanalization. At I, 2, or 4 h post-MCAO, rats were killed by transcardial perfusion with heparinized saline followed by 4% paraformaldehyde.
Adjacent vibratome sections were cut for H&E staining (25 j.Lm) and MAP2 immunohistochemistry (50 j.Lm). Im munohistochemistry was performed on free-floating sec tions using the avidin-biotin peroxidase complex tech nique and 3,3' -diaminobenzidine as peroxidase substrate. Preliminary blocking was carried out by incubation (2-3 h) in normal horse serum. The primary and secondary antibodies were monoclonal mouse anti-MAP2 (1:4,000 dilution, 15-h incubation; Amersham) and biotinylated anti-mouse IgG (l :200 dilution in 5% rat plasma to mini mize cross-reactivity, I-h incubation; Vector). For con trols, the primary antibody was omitted or replaced with mouse IgG. Stained sections were mounted onto glass slides and examined by light microscopy.
Volumetric analysis was subsequently performed on MAP2-stained sections using the method originally de scribed by Osborne et al. (1987) . Lesion borders from sections corresponding to eight preselected stereotaxic levels were transcribed onto scale drawings. Lesion areas were then measured from these drawings using an image analyzer and converted to total volume of ischemic dam age using the known distance between each of the eight chosen levels. leading to dephosphorylation and proteolytic degra dation of MAP2 (Siman and Noszek, 1988; Halpain and Greengard, 1990) . In contrast to our findings of rapid MAP2 loss, a previous report found a signif icant reduction in MAP2 only after 72 h of perma nent MCAO (Inuzuka et aI. , 1990) . However, this study analyzed MAP2 levels in the entire cerebral hemisphere, and thus a comparatively small, local ized reduction in cortical MAP2 may have been masked at time points earlier than 3 days following MCAO. In our study, some cellular elements in the ven tral core of the lesion exhibited a marked increase in staining for MAP2, a phenomenon that has also been reported following transient global ischemia (Miyazawa et aI., 1993; Geddes et aI. , 1994) and attributed to either an increase in neuronal staining (Geddes et aI., 1994) or a novel expression of MAP2 in reactive astrocytes (Miyazawa et aI. , 1993) . Our study suggests that (at least in the acute phase) fol lowing focal ischemia, the increase in MAP2 immu nostaining occurs in neurons rather than astrocytes since cells that stained for MAP2 were not labeled for glial fibrillary acidic protein. The reasons for increased MAP2 immunostaining are unclear but are unlikely to reflect merely a change in antigenic ity of MAP2 in response to changes in the phos phorylation state of the protein (Hal pain and Green gard, 1990; Tomimoto and Yanagihara, 1992) and may instead reflect up-regulation of MAP2, perhaps in response to nitric oxide (Johnston and Morris, 1994) .
RESULTS
In conclusion, we have demonstrated that perma nent focal ischemia results in a rapid reduction in MAP2 immunostaining. Furthermore, the region borders defined by this loss of MAP2 can be mea sured to give a volumetric assessment of acute focal ischemic brain injury. Thus, loss of MAP2 immu no staining may prove to be a useful, quantifiable marker of brain damage following acute focal isch emia particularly where methodological constraints (such as in experiments utilizing multiple label im munohistochemistry) preclude the use of more con ventional histological techniques.
